Processa Pharmaceuticals, Inc.
PCSA
$0.2294
-$0.0059-2.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.78M | 4.91M | 4.79M | 4.46M | 5.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.05M | 11.79M | 10.53M | 10.16M | 11.46M |
| Operating Income | -12.05M | -11.79M | -10.53M | -10.16M | -11.46M |
| Income Before Tax | -11.85M | -11.53M | -10.22M | -9.83M | -11.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.85 | -11.53 | -10.22 | -9.83 | -11.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.85M | -11.53M | -10.22M | -9.83M | -11.12M |
| EBIT | -12.05M | -11.79M | -10.53M | -10.16M | -11.46M |
| EBITDA | -12.05M | -11.79M | -10.53M | -9.96M | -11.06M |
| EPS Basic | -3.93 | -4.86 | -5.36 | -6.29 | -8.72 |
| Normalized Basic EPS | -2.45 | -3.03 | -3.35 | -3.93 | -5.45 |
| EPS Diluted | -3.93 | -4.86 | -5.36 | -6.29 | -8.72 |
| Normalized Diluted EPS | -2.45 | -3.03 | -3.35 | -3.93 | -5.45 |
| Average Basic Shares Outstanding | 12.24M | 10.13M | 8.21M | 6.57M | 5.24M |
| Average Diluted Shares Outstanding | 12.24M | 10.13M | 8.21M | 6.57M | 5.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |